Canopus BioPharma, Inc. (OTC:CBIA); (www.canopusbiopharma.com) today announced that it has successfully completed the second...
LOS ANGELES, California and GUANGZHOU, China, August 12 /PRNewswire-FirstCall/ -- - Major Threat Treatable With StatC(TM); FDA-Approved Drugs to...
Canopus BioPharma, Inc. (OTC: CBIA), is pleased to announce that the South African Medicines Control Council has granted approval...
Canopus BioPharma, Inc. (OTC: CBIA), has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and...
LOS ANGELES, California, June 18 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc. (OTC:CBIA), a biotechnology company developing pharmaceutical...
Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients...
Canopus BioPharma, Inc. (OTCPK: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients...
Drake Holding Corp. (DRKH.PK) announced that its corporate name has been officially changed to Canopus BioPharma, Inc. and, to...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.